Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Omega-3s show promise for kids with ADHD and inflammation

NCT ID NCT07348562

Symptom relief Sponsor: China Medical University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether high-dose omega-3 fatty acids can reduce ADHD symptoms in children aged 6-12 who have high inflammation levels. Fifteen children took omega-3 supplements for 12 weeks. Researchers measured changes in ADHD symptoms and inflammatory markers to see if omega-3s could help ease the condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

Feb 2021

Finished

Nov 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of ADHD (DSM-5) made by a child and adolescent psychiatrist. * Age range: 6-12 years old at the time of enrollment. * SNAP-IV (Mandarin Chinese Version): Inattention subscale score \> 12 or Hyperactivity/impulsivity subscale score \> 12 or Total score \> 24 * Drug-naïve or no ADHD medication use in the past 6 months. * Signed informed consent required. Exclusion Criteria: * Intelligence quotient \<80 * Comorbid other psychiatric disorders, such as autism spectrum disorder, anxiety disorder, conduct disorder, schizophrenia, mood disorder * Comorbid physical disorders, such as thyroid dysfunction, cerebral palsy, coagulation disorders * Currently using omega-3 supplements * Allergy to omega-3

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADHD

Contacts and locations

Locations

  • China Medical University

    Taichung, Taichung, 404, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.